MX2017008074A - DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). - Google Patents

DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).

Info

Publication number
MX2017008074A
MX2017008074A MX2017008074A MX2017008074A MX2017008074A MX 2017008074 A MX2017008074 A MX 2017008074A MX 2017008074 A MX2017008074 A MX 2017008074A MX 2017008074 A MX2017008074 A MX 2017008074A MX 2017008074 A MX2017008074 A MX 2017008074A
Authority
MX
Mexico
Prior art keywords
pi3kß
inhibitors
compounds
imidazopyridazine derivatives
present
Prior art date
Application number
MX2017008074A
Other languages
English (en)
Spanish (es)
Inventor
Lieven Meerpoel
Sophie Coupa
Laurence Anne Mevellec
Virginie Sophie Poncelet
Christophe Meyer
Elisabeth Thérèse Jeanne Pasquier
Patrick René Angibaud
Isabelle Noëlle Constance Pilatte
Didier Jean-Claude Berthelot
Alexis Georges Querolle Olivier
Jean Maurice MERCEY Guillaume
Gabriel Marcel DEMESTRE Christophe
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017008074A publication Critical patent/MX2017008074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Taps Or Cocks (AREA)
MX2017008074A 2014-12-19 2015-12-18 DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). MX2017008074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS

Publications (1)

Publication Number Publication Date
MX2017008074A true MX2017008074A (es) 2018-01-09

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008074A MX2017008074A (es) 2014-12-19 2015-12-18 DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).

Country Status (26)

Country Link
US (1) US10087187B2 (enExample)
EP (1) EP3233862B1 (enExample)
JP (1) JP6568588B2 (enExample)
KR (1) KR20170095239A (enExample)
CN (1) CN107108634B (enExample)
AU (1) AU2015366190B2 (enExample)
BR (1) BR112017012930A2 (enExample)
CA (1) CA2967551A1 (enExample)
CY (1) CY1122381T1 (enExample)
DK (1) DK3233862T3 (enExample)
EA (1) EA029789B1 (enExample)
ES (1) ES2761051T3 (enExample)
HR (1) HRP20191550T1 (enExample)
HU (1) HUE045220T2 (enExample)
IL (1) IL252866B (enExample)
LT (1) LT3233862T (enExample)
MA (1) MA41174B1 (enExample)
MD (1) MD3233862T2 (enExample)
ME (1) ME03517B (enExample)
MX (1) MX2017008074A (enExample)
PL (1) PL3233862T3 (enExample)
PT (1) PT3233862T (enExample)
RS (1) RS59301B1 (enExample)
SI (1) SI3233862T1 (enExample)
SM (1) SMT201900509T1 (enExample)
WO (1) WO2016097347A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382601B (es) 2015-10-09 2025-03-13 Janssen Pharmaceutica Nv DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
HRP20210508T1 (hr) 2016-06-16 2021-05-28 Janssen Pharmaceutica Nv Biciklički derivati piridina, pirazina i pirimidina kao inhibitori pi3k beta
EA201992296A1 (ru) 2017-03-29 2020-02-12 Янссен Фармацевтика Нв Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
IL285315B2 (en) 2019-02-07 2025-12-01 Beigene Ltd Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US20090215818A1 (en) 2006-07-24 2009-08-27 Smithkline Beecham Corporation Thiozolidinedione derivatives as pi3 kinase inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
KR20100019489A (ko) * 2007-05-09 2010-02-18 노파르티스 아게 Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
UY31676A1 (es) * 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP3170813B1 (en) * 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
HUE045220T2 (hu) 2019-12-30
JP6568588B2 (ja) 2019-08-28
DK3233862T3 (da) 2019-10-07
WO2016097347A1 (en) 2016-06-23
AU2015366190A1 (en) 2017-05-25
PT3233862T (pt) 2019-10-09
ES2761051T3 (es) 2020-05-18
US20180002336A1 (en) 2018-01-04
EA201791396A1 (ru) 2017-10-31
PL3233862T3 (pl) 2020-01-31
AU2015366190B2 (en) 2020-01-23
KR20170095239A (ko) 2017-08-22
EA029789B1 (ru) 2018-05-31
SI3233862T1 (sl) 2019-09-30
SMT201900509T1 (it) 2019-11-13
LT3233862T (lt) 2019-09-10
JP2017538734A (ja) 2017-12-28
MA41174B1 (fr) 2019-09-30
IL252866B (en) 2020-09-30
CN107108634B (zh) 2020-09-15
US10087187B2 (en) 2018-10-02
MD3233862T2 (ro) 2019-11-30
HRP20191550T1 (hr) 2019-11-29
RS59301B1 (sr) 2019-10-31
ME03517B (me) 2020-04-20
BR112017012930A2 (pt) 2018-01-09
CA2967551A1 (en) 2016-06-23
IL252866A0 (en) 2017-08-31
CY1122381T1 (el) 2021-01-27
EP3233862B1 (en) 2019-07-03
MA41174A (fr) 2017-10-25
EP3233862A1 (en) 2017-10-25
CN107108634A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
MX2022005182A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
NZ725399A (en) Macrocylic pyrimidine derivatives
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
MX2016012994A (es) Derivados de piridina macrociclicos.
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2020005944A (es) Analogos espirobiciclicos novedosos.
MX378732B (es) Formas solidas novedosas
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MY197698A (en) Oxysterols and methods of use thereof
PH12016501462A1 (en) Neprilysin inhibitors
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
PH12018501895A1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration